The advancements made by the project facilitated long-lasting transnational collaborations between SMEs, the development of innovation, and assisted in the introduction of these products into the market.
One of the regional ‘Access Brokers’, Céline Queron, explained the benefits of her participation: “IN2LifeSciences allowed us to offer more opportunities, by sourcing cutting-edge expertise outside of France. This also enabled us to share the expertise present within our region more widely, by working with businesses in other areas of North-West Europe.”
Another successful example was an SME in Hemarina, France. The company developed an additive for donor organ preservation solutions that allowed oxygenation and minimised the risk of rejection. However, before it could be marketed, the company had to ensure it would be sterile, and needed a connection to a company that provided sterilisation services. In Belgium, a company called Sterigenics could supply a sterilisation technology known as irradiation, but they needed a link to other Life Science companies working in medical technology innovation.
Using their incentive program, the IN2LifeSciences project helped the two companies meet and work together. Hemarina was then able to test the technology and proceed with manufacturing. The result was a new, transnational collaboration, a decrease in the amount of time it took to take their innovation to market, and better access for consumers and health care providers to life-changing new services.
In each case, IN2LifeSciences stimulated cross-border cooperation and innovation, created new opportunities, and helped important medical technologies and life science companies gain a competitive advantage.